| Ytd | -25.31% | |
| 1y | -33.88% |
| Open | 1.18 | Prev Close | 1.23 | Low | 1.18 | High | 1.25 | Mkt Cap | 45.55M |
| Vol | 132.99K | Avg Vol | 173.79K | EPS | -2.30 | P/E | -0.53 | Forward P/E | -1.38 |
| Beta | 0.66 | Short Ratio | 0.60 | Inst. Own | 34.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 1.24 | 200-d Avg | 1.53 | 1yr Est | 18.40 |
MGX News
Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.73 per share versus the Zacks Con
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Transcript
EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswir
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be lim
EMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (th
Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.61 per share versus the Zacks Con
On track for regulatory submission of MGX-001 to advance global clinical program, including investig
Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) has earned a consensus recommendation of "Moderate
Metagenomi Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary C
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be lim
Metagenomi (NASDAQ: MGX - Get Free Report) is expected to be issuing its Q4 2025 results before the
Shares of Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) have been given a consensus rating of "Mo
Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.6 per share versus the Zacks Cons
Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity i
Metagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference Transcri
EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (t
MGX Resources Limited (MTGRY) Q2 2026 Earnings Call Prepared Remarks Transcript
HIAB CORPORATION, PRESS RELEASE, 9 FEBRUARY 2026 AT 3:00 PM (EET) Hiab expands US footprint with app
Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) shares dropped 1.2% during trading on Monday. The s
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a str
